PHAT logo

Phathom Pharmaceuticals, Inc. Common Stock


PHAT: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.


Show PHAT Financials

Consumer Interest
SEC Filings

Recent trades of PHAT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by PHAT's directors and management

Government lobbying spending instances

  • $10,000 Apr 19, 2021 Issue: Health Issues
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of PHAT in WallStreetBets Daily Discussion


Recent insights relating to PHAT

CNBC Recommendations

Recent picks made for PHAT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PHAT

Corporate Flights

Flights by private jets registered to PHAT